Ad
related to: myasthenia gravis fact sheet
Search results
Results from the WOW.Com Content Network
Myasthenia gravis (MG) is a long-term neuromuscular junction disease that leads to varying degrees of skeletal muscle weakness. [1] The most commonly affected muscles are those of the eyes, face, and swallowing. [1][5] It can result in double vision, drooping eyelids, and difficulties in talking and walking. [1]
Rare. Transient neonatal myasthenia gravis, i.e., TNMG (also termed neonatal myasthenia gravis [1]), and its more severe form, fetal acetylcholine receptor inactivation syndrome (i.e., FARIS), is one of the various types of myasthenia gravis (i.e., MG). [2] MG is an autoimmune disease in which individuals form antibodies that circulate in their ...
Myasthenia gravis. Myasthenia gravis is an autoimmune disease affecting synapses at the neuromuscular junction, whereby antibodies produced primarily in the thymus gland by B-cells associate with postsynaptic nicotinic acetylcholine receptors (AChR), along with other NMJ post-synaptic receptors (MuSK-R and low-density lipoprotein receptor).
The company is testing its drug, inebilizumab or Uplizna, in patients suffering from myasthenia gravis, which is caused by an abnormal immune reaction that weakens the muscles that control the ...
Oculopharyngeal muscular dystrophy (OPMD) is a rare form of muscular dystrophy with symptoms generally starting when an individual is 40 to 50 years old. It can be autosomal dominant neuromuscular disease or autosomal recessive. The most common inheritance of OPMD is autosomal dominant, which means only one copy of the mutated gene needs to be ...
The National Institute of Neurological Disorders and Stroke (NINDS) is a part of the U.S. National Institutes of Health (NIH). It conducts and funds research on brain and nervous system disorders and has a budget of just over US$2.03 billion. [2] The mission of NINDS is "to reduce the burden of neurological disease—a burden borne by every age ...
C2310H3554N602O692S14. Molar mass. 51 280.20 g·mol −1. Efgartigimod alfa, sold under the brand name Vyvgart, is a medication used to treat myasthenia gravis. [3][4] Efgartigimod alfa is a neonatal Fc receptor blocker and is a new class of medication. [4] It is an antibody fragment that binds to the neonatal Fc receptor (FcRn), preventing ...
In myasthenia gravis, there is a variable weakness of skeletal muscles, which is exacerbated by repeated contraction. To cause sustained contraction of levator palpebrae superioris muscle, the patient is asked to gaze upward for an extended period of time, without lifting the head.
Ad
related to: myasthenia gravis fact sheet